$36.39
-0.01-0.03%
Last update: Nov 3, 5:09 PM
Pacira BioSciences Inc
PCRXNASDAQ
Pacira BioSciences (PCRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Pacira BioSciences (PCRX) last issued guidance on August 4, 2026 for fiscal year 2026. The company guided revenue in the range of $735M - $760M for the period.
Compared to prior guidance, Pacira BioSciences lowered its revenue forecast from a prior range of $745M - $770M.
Pacira BioSciences has issued 16 guidance updates between January 5, 2023 and August 4, 2026. During this period, the company raised its outlook 5 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.57 | $0.52 | $0.78 | $0.56 |
| Actual | $0.73 | $0.60 | $0.57 | $0.70 |
| Surprise | +28.1% | +15.4% | -26.9% | +25.0% |
| Revenue | ||||
| Estimate | $190.9M | $173.9M | $200.0M | $182.4M |
| Actual | $192.4M | $177.4M | $196.9M | $179.5M |
| Surprise | +0.79% | +1.97% | -1.54% | -1.57% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.68 | $0.78 | $0.41 | $0.42 |
| Revenue | ||||
| Consensus | $183.0M | $201.9M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.73 | $0.57 | 28.1 % |
| Q1 | Apr 30, 2026 | $0.60 | $0.52 | 15.4 % |
| Q4 | Feb 26, 2026 | $0.57 | $0.78 | -26.9 % |
| Q3 | Nov 6, 2025 | $0.70 | $0.56 | 25.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $192.40M | $190.89M | 0.79 % |
| Q1 | Apr 30, 2026 | $177.38M | $173.95M | 1.97 % |
| Q4 | Feb 26, 2026 | $196.87M | $199.95M | -1.54 % |
| Q3 | Nov 6, 2025 | $179.52M | $182.38M | -1.57 % |
